Barinthus Biotherapeutics plc Overview
Pro stress-test →Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapies to treat autoimmune and inflammatory diseases. The company is undergoing a transformational merger with Clywedog Therapeutics, expected to close in H1 2026, positioning itself to target Type 1/2 diabetes and celiac disease with a focused pipeline of clinical-stage assets.
Strategic Profile
Pro stress-test →The company leverages two proprietary platform technologies—viral vector-based (ChAdOx/MVA) and synthetic SNAP-Tolerance Immunotherapy (SNAP-TI)—to develop antigen-specific immune tolerance therapies. With $87.8M in cash and runway extending into 2027, Barinthus is advancing lead candidate VTP-1000 in celiac disease with Phase 1 data expected in Q4 2025, while also pursuing partnerships to monetize its broader portfolio.
Competitive Landscape
Pro stress-test →Barinthus competes in the clinical-stage immunotherapy space against Inovio Pharmaceuticals, VBI Vaccines, uniQure, Alaunos Therapeutics, and Beam Therapeutics. Differentiation lies in its SNAP-TI synthetic platform enabling antigen-specific immune tolerance—a less crowded mechanism versus checkpoint inhibitors and CAR-T approaches dominating the cancer immunotherapy market.
Industry Context
Barinthus Biotherapeutics plc operates in Clinical-Stage Biopharmaceuticals - Immunotherapy & Autoimmune Diseases.
Key facts
Founded: 2016 · Headquarters: Didcot, United Kingdom · Revenue: $15.0M · Market cap: $24.5M